美国喉鳞状细胞癌发病率和生存趋势:基于人群的二十年分析
基于监测、流行病学和最终结果数据库分析2000至2019年46 266例喉鳞状细胞癌,年龄调整发病率为每10万人年2.7例,年百分比变化为-2.6%(95%CI:-2.8%至2.4%);初诊年龄从64.6岁增至66.0岁(p<0.001),晚期T分期从18%增至23%(p<0.001),以化放疗为主要治疗的比例从20.0%增至27.0%(p<0.001);多因素分析显示疾病特异生存和总生存随5年区间逐步改善,主要体现在晚期疾病。
要点
- 2000至2019年喉鳞状细胞癌年龄调整发病率为每10万人年2.7例,年百分比变化为-2.6%(95%CI:-2.8%至2.4%)。
- 初诊年龄从64.6岁增至66.0岁(p<0.001),晚期T分期从18%增至23%(p<0.001)。
- 以化放疗为主要治疗的比例从20.0%增至27.0%(p<0.001),多因素分析显示生存逐步改善。
核心结论
- 喉鳞状细胞癌年龄调整发病率逐步显著下降,同时以化放疗为主要治疗的使用增加;校正相关特征后,研究期间生存持续改善,主要体现在晚期疾病。
研究设计与样本
- 利用监测、流行病学和最终结果数据库识别2000至2019年喉鳞状细胞癌的年龄调整发病率,共46 266例。
- 采用连接点回归识别年百分比变化,卡方分析用于发现研究期间人口学、临床病理和治疗变化,单因素Kaplan-Meier和多因素COX回归用于识别生存差异。
主要发现
- 2000至2019年共识别46 266例喉鳞状细胞癌,年龄调整发病率为每10万人年2.7例,年百分比变化为-2.6%(95%CI:-2.8%至2.4%)。
- 初诊年龄从64.6岁增至66.0岁(p<0.001)。
- 较高家庭收入中位数与较低年龄调整发病率相关(35 000美元以下为5.3;75 000美元以上为2.2),且与更大的年百分比下降相关(35 000美元以下为-1.1%*;75 000美元以上为-3.2%*)。
- 研究期间晚期T分期诊断增加(T3从18%增至23%,p<0.001),以化放疗为主要治疗显著增加(从20.0%增至27.0%,p<0.001)。
- 单因素分析生存无显著差异;多因素分析显示疾病特异生存和总生存随5年区间逐步改善,晚期疾病在每个治疗时期单因素和多因素分析均显示生存逐步改善。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Laryngeal cancer has undergone a complex evolution in incidence, management, and standards of care over the past 20 years. Disease-wide demographic and survival risk factors have yet to be elucidated. OBJECTIVE: Examine incidence, management, and survival trends in laryngeal cancer from 2000 to 2019. DESIGN, SETTING, AND PARTICIPANTS: The Surveillance, Epidemiology, and End Results database was utilized to identify age-adjusted incidence rates (AAIRs) of laryngeal squamous cell carcinoma (LSCCa) from 2000 to 2019. Joinpoint regression was conducted to identify annual percentage changes (APCs). Chi-squared analysis was used to find changes in demographic, clinicopathologic, and treatment changes over the study period. Finally, univariate Kaplan-Meier and COX multivariate regressions were conducted to identify survival differences. RESULTS: There were 46 266 cases of LSCCa identified between 2000 and 2019 with AAIR of 2.7 per 100 000 person-years with APC of -2.6% [95% CI: -2.8% to 2.4%]. These rates have largely been down-trending among demographic substratifications. Age at initial diagnosis has been increasing (64.6 → 66.0, p < 0.001). Higher median household income was associated with lower AAIR (35 000 5.3; > $75 000 2.2) and increased annual percentage decrease (< $35 000, -1.1%*; > $75 000, -3.2%*). There were no other clinically significant differences in demographic and clinicopathologic trends although persistent demographic differences were noted. Late T-stage at diagnosis has increased over the study period (T3, 18% → 23%, p < 0.001). Treatment with primary chemoradiotherapy has increased significantly (20.0% → 27.0%, p < 0.001). On univariate analysis, there were no significant differences in survival; however, on multivariate analysis, there has been a progressive improvement in disease-specific and overall survival over 5-year bins. Late-stage disease had a progressive improvement in survival with each treatment period on both univariate and multivariate analysis. CONCLUSIONS AND RELEVANCE: There has been a progressively significant decrease in age-adjusted incidence of LSCCa with increased utilization of primary chemoradiotherapy. When adjusted for associated characteristics, there has been a continuing improvement in survival over the study period, primarily in late-stage disease.
引用
- Sangal NR, Xu K, Kaki P, et al. Laryngeal Squamous Cell Carcinoma Incidence and Survival Trends in the United States: A Population-Based Analysis of Two Decades. Head Neck. 2025. PMID: 39891399. doi:10.1002/hed.28077
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。